Why Investors Should Love Celgene Corporation (CELG)’s Apremilast

Page 1 of 2

Celgene Corporation (NASDAQ:CELG) shareholders didn’t have to wait long for good news in 2013. On Jan. 7, the company announced positive results for two phase 3 studies of apremilast in treating psoriasis. Is apremilast really that big of a deal for Celgene investors? You bet. Here’s why.

All in the family
The clinical success of apremilast is yet another feather in the cap of Celgene’s research and development. It also reflects a continuation of the company’s long history with its granddaddy of drugs, Thalomid. While Thalomid certainly had its ups and downs over nearly 60 years, Celgene’s research with analogs of the drug paid off tremendously with Revlimid, Pomalyst, and now apremilast.

Celgene Corporation (NASDAQ:CELG)Despite being in the same family tree as the other drugs, apremilast works quite differently. It also belongs to another family of drugs called phosphodiesterase type 4, or PDE4, inhibitors. These drugs block the enzyme PDE4, which breaks down cyclic adenosine monophosphate, or cAMP. The problem with this is that cAMP is important in extracellular signaling known as signal transduction. In a nutshell, too much of a breakdown in cAMP by these PDE4 enzymes means that the human body isn’t a happy camper.

PDE4 inhibitors have shown potential for treating a variety of indications, including chronic obstructive pulmonary disease, asthma, depression, Alzheimer’s disease, and Parkinson’s disease. Celgene Corporation (NASDAQ:CELG)’s focus with apremilast, though, has been on treating inflammatory conditions. Apremilast increases cAMP levels, which then reduces inflammatory responses in cells.

Why investors should love it
So, why should investors love apremilast? Let us count the ways.

Celgene’s first New Drug Application, or NDA, for apremilast will be for psoriatic arthritis. The company expects to submit that NDA in the first quarter, followed by another for psoriasis in the second half of 2013. A combined Marketing Authorization Application, or MAA, for both indications will be submitted in Europe also in the second half of the year.

Psoriatic arthritis and psoriasis present a significant market potential. As many as 125 million people across the world have psoriasis, including up to 7.5 million Americans. Between 10% and 30% of those individuals also develop psoriatic arthritis.

Of course, this huge market already has several major drugs in the mix. AbbVie Inc (NYSE:ABBV)‘s Humira currently stands as the biggest player, followed by Enbrel from Amgen, Inc. (NASDAQ:AMGN) and Pfizer Inc. (NYSE:PFE) and two drugs from Johnson & Johnson (NYSE:JNJ): Remicade and Simponi. Can Celgene realistically expect to compete against these biologic juggernauts? I think it can.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

The 10 Largest Armies in the World: Who Should We Be Afraid Of?

Best Warren Buffett Quotes on Money You Need to Hear

The 10 Highest Suicide Rates by Profession

The 20 Most Underrated Movies of All Time

The 10 Fastest Growing Companies in America

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!